CFTR and cystic fibrosis: Ongoing efforts to rationalize the molecular basis for the diverse responses of clinical CF variants to various CFTR modulators have revealed that pharmacological responses coincide with changes in the CFTR interactome.7–10 Misfolded CFTR variants typically form numerous aberrant interactions with cellular quality control (QC) proteins, many of which are lost upon successful rescue with CFTR modulators.9,10 These perturbations of the CFTR interactome vary considerably across CF variants with distinct theratypes.